#gsk — Public Fediverse posts

Halifax

Important information Halifax Share Dealing Limited. Registered in England and Wales no. 3195646. Registered Office: Trinity Road, Halifax,…
#EuropeSays #Britain #Europe #EU #GSK #BrokerOnLine
https://www.europesays.com/britain/86383/

EMA Accepts GSK’s Bexsero Booster Label Update for Single-Dose Meningitis B Vaccine in Individuals Aged 10 and Above

Disclaimer The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions,…
#EuropeSays #Britain #Europe #EU #GSK
https://www.europesays.com/britain/86370/

GSK Discontinues Development of Camlipixant for Refractory Chronic Cough

GSK plc GSK has announced that it is discontinuing development of camlipixant, an investigational P2X3 receptor antagonist, for the…
#EuropeSays #Britain #Europe #EU #GSK #chroniccough #development #EPSestimates #GSKplc #ZacksInvestmentResearch
https://www.europesays.com/britain/85910/

https://www.europesays.com/britain/85910/ GSK Discontinues Development of Camlipixant for Refractory Chronic Cough #ChronicCough #development #EPSEstimates #GSK #GSKPlc #ZacksInvestmentResearch

GSK ends camlipixant RCC program after mixed results | GSK SEC Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER…
#EuropeSays #Britain #Europe #EU #GSK #BALANCEtrial #CALM-1 #CALM-2 #camlipixant #GSKplc #IBS-D #PhaseIIItrials #refractorychroniccough #SECForm6-K
https://www.europesays.com/britain/85320/

GSK to re-appoint Deloitte as external auditor | GSK SEC Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER…
#EuropeSays #Britain #Europe #EU #GSK #6-Kfiling #annualgeneralmeeting #audittender #corporategovernance #deloitte #externalauditor #GSKplc #PublicInterestEntity #statutoryaudit
https://www.europesays.com/britain/85086/

https://www.europesays.com/britain/85086/ GSK to re-appoint Deloitte as external auditor | GSK SEC Filing #6KFiling #AnnualGeneralMeeting #AuditTender #CorporateGovernance #deloitte #ExternalAuditor #GSK #GSKPlc #PublicInterestEntity #StatutoryAudit

GSK executives acquire ADSs via dividend reinvestment | GSK SEC Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER…
#EuropeSays #Britain #Europe #EU #GSK #AmericanDepositaryShares #dividendreinvestment #Form6-K #GSKADS #GSKplc #InsiderTransactions #NYSE
https://www.europesays.com/britain/84773/

https://www.europesays.com/britain/84773/ GSK executives acquire ADSs via dividend reinvestment | GSK SEC Filing #AmericanDepositaryShares #DividendReinvestment #Form6K #GSK #GSKADS #GSKPlc #InsiderTransactions #NYSE

Nuvalent director’s awards cashed out in GSK deal

SEC Form 4 FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP…
#EuropeSays #Britain #Europe #EU #GSK #Form4 #GlaxoSmithKline #InsiderTrading #merger #Nuvalent #NUVL #OfferPrice #SapnaSrivastava #stockoptions #tenderoffer
https://www.europesays.com/britain/83997/

https://www.europesays.com/britain/83997/ Nuvalent director’s awards cashed out in GSK deal #Form4 #GlaxoSmithKline #GSK #InsiderTrading #merger #Nuvalent #NUVL #OfferPrice #SapnaSrivastava #StockOptions #TenderOffer

Nuvalent director tenders shares in $124 GSK buyout

SEC Form 4 FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP…
#EuropeSays #Britain #Europe #EU #GSK #directordisposition #GlaxoSmithKlinemerger #insidertransaction #Nuvalent #NUVL #restrictedstockunits #stockoptions #tenderoffer
https://www.europesays.com/britain/83982/

https://www.europesays.com/britain/83982/ Nuvalent director tenders shares in $124 GSK buyout #DirectorDisposition #GlaxoSmithKlineMerger #GSK #InsiderTransaction #Nuvalent #NUVL #RestrictedStockUnits #StockOptions #TenderOffer

GSK Completes Nuvalent Tender Offer at $124 Per Share | NUVL SEC Filing

This Amendment No. 4 (this “Amendment”) amends and supplements the Tender Offer Statement on Schedule TO (together with any…
#EuropeSays #Britain #Europe #EU #GSK #$124pershare #acquisition #merger #Nasdaqdelisting #Nuvalent #NUVL #Section251(h) #tenderoffer
https://www.europesays.com/britain/83666/

https://www.europesays.com/britain/83666/ GSK Completes Nuvalent Tender Offer at $124 Per Share | NUVL SEC Filing #$124PerShare #acquisition #GSK #merger #NasdaqDelisting #Nuvalent #NUVL #Section251(h) #TenderOffer

GSK Eyes FDA Filing After Immunotherapy Succeeds in Key Rectal Cancer Study

GSK has results from a pivotal clinical trial showing rectal cancer patients treated with its drug avoided the…
#EuropeSays #Britain #Europe #EU #GSK #biopharmanl #Cancer #ClinicalTrials #FDA #immunotherapy #Jemperli #rectalcancer
https://www.europesays.com/britain/83064/

https://www.europesays.com/britain/83064/ GSK Eyes FDA Filing After Immunotherapy Succeeds in Key Rectal Cancer Study #BiopharmaNl #Cancer #ClinicalTrials #FDA #GSK #immunotherapy #Jemperli #RectalCancer

GSK’s Jemperli Delivers Promising Interim Data in Rectal Cancer

GSK plc GSK has announced positive interim data from a mid-stage study evaluating its oncology drug, Jemperli (dostarlimab), in…
#EuropeSays #Britain #Europe #EU #GSK #approvedindications #endometrialcancers #GSKplc #Jemperli #mismatchrepair #OncologyDrug #Patients #rectalcancer #ZacksInvestmentResearch
https://www.europesays.com/britain/83022/

https://www.europesays.com/britain/83022/ GSK’s Jemperli Delivers Promising Interim Data in Rectal Cancer #ApprovedIndications #EndometrialCancers #GSK #GSKPlc #Jemperli #MismatchRepair #OncologyDrug #Patients #RectalCancer #ZacksInvestmentResearch

Surgery-Free Rectal Cancer Treatment Edges Closer as Dostarlimab Clears Registrational Trial

GSK announced Sunday that dostarlimab (Jemperli), its PD-1–blocking immunotherapy, met the primary endpoint of the AZUR-1 registrational Phase…
#EuropeSays #Britain #Europe #EU #GSK #AZUR-1trial #cancertreatment #dostarlimab #FDAapproval #immunotherapy #Jemperli #rectalcancer
https://www.europesays.com/britain/82987/

https://www.europesays.com/britain/82987/ Surgery-Free Rectal Cancer Treatment Edges Closer as Dostarlimab Clears Registrational Trial #AZUR1Trial #CancerTreatment #dostarlimab #FDAApproval #GSK #immunotherapy #Jemperli #RectalCancer

https://www.europesays.com/britain/82748/ GSK’s Jemperli Delivers Promising Interim Data in Rectal Cancer – July 14, 2026 #Financial #FinancialPlanning #GSK #investing #INVESTMENT #InvestmentAdvice #OnlineInvestment #OnlineStockTrading #OnlineTrading #quote #quotes #stock #StockMarket #StockQuotes #stocks

GSK leaders acquire shares via reward and dividends | GSK SEC Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER…
#EuropeSays #Britain #Europe #EU #GSK #dividendreinvestment #Form6-K #GSKplc #InsiderTransactions #LSE #ordinaryshares #sharerewardplan
https://www.europesays.com/britain/82192/

https://www.europesays.com/britain/82192/ GSK leaders acquire shares via reward and dividends | GSK SEC Filing #DividendReinvestment #Form6K #GSK #GSKPlc #InsiderTransactions #LSE #OrdinaryShares #ShareRewardPlan

GSK reports Jemperli rectal cancer trial results

GSK reported positive interim results from the AZUR-1 Phase II trial of Jemperli in dMMR/MSI-H locally advanced rectal…
#EuropeSays #Britain #Europe #EU #GSK #AZUR-1trial #Biotechnology #cancertreatment #dostarlimab #GSKplc #immunotherapy #Jemperli #Oncology #rectalcancer
https://www.europesays.com/britain/82130/

https://www.europesays.com/britain/82130/ GSK reports Jemperli rectal cancer trial results #AZUR1Trial #Biotechnology #CancerTreatment #dostarlimab #GSK #GSKPlc #immunotherapy #Jemperli #Oncology #RectalCancer

GSK’s partner Hansoh Pharma succeeds in Chinese Phase III SCLC ADC trial

GSK’s bet on Hansoh Pharmaceutical’s antibody-drug conjugate (ADC) seems to be paying off as the drug met all…
#EuropeSays #Britain #Europe #EU #GSK #antibodydrugconjugate #China #ES-SCLC #HansohPharma #HansohPharmaceutical #Lungcancer #mainlandChina #PhaseIII #PhaseIIItrial #ris-rez
https://www.europesays.com/britain/82012/

https://www.europesays.com/britain/82012/ GSK’s partner Hansoh Pharma succeeds in Chinese Phase III SCLC ADC trial #AntibodyDrugConjugate #China #ESSCLC #GSK #HansohPharma #HansohPharmaceutical #LungCancer #MainlandChina #PhaseIII #PhaseIIITrial #RisRez

GSK’s Jemperli meets main goal in mid-stage rectal cancer trial

GSK said on Monday its cancer drug Jemperli met the primary goal of a mid-stage trial, with a…
#EuropeSays #Britain #Europe #EU #GSK #AZUR-1trial #cancerdrugapproval #chemotherapyalternatives #ClinicalTrialResults #dostarlimab #immunotherapy #Jemperli #mid-stagetrial #rectalcancertrial
https://www.europesays.com/britain/81923/

https://www.europesays.com/britain/81923/ GSK’s Jemperli meets main goal in mid-stage rectal cancer trial #AZUR1Trial #CancerDrugApproval #ChemotherapyAlternatives #ClinicalTrialResults #dostarlimab #GSK #immunotherapy #Jemperli #MidStageTrial #RectalCancerTrial

GSK Reports Encouraging Phase II Results for Jemperli in Rectal Cancer Study (GSK)

GSK ©Adobe Stock Images GSK (LSE:GSK) has announced positive interim results from the Phase II AZUR-1 trial evaluating…
#EuropeSays #Britain #Europe #EU #GSK #Jemperli #rectalcancer
https://www.europesays.com/britain/81908/

https://www.europesays.com/britain/81908/ GSK Reports Encouraging Phase II Results for Jemperli in Rectal Cancer Study (GSK) #GSK #Jemperli #RectalCancer

GSK, Hansoh Lung Cancer Drug Hits Main Survival Goal in China Trial

British drugmaker GSK and its Chinese partner Hansoh Pharmaceutical have reported that their targeted cancer therapy, known as…
#EuropeSays #Britain #Europe #EU #GSK #antibodydrugconjugate #cancertreatmentinnovation #Chinaclinicaltrial #globaloncologypipeline #HansohPharmaceutical #Oncology #overallsurvival #Phase3trial #progression-freesurvival #ris-rez #smallcelllungcancer #targetedtherapy
https://www.europesays.com/britain/81834/

https://www.europesays.com/britain/81834/ GSK, Hansoh Lung Cancer Drug Hits Main Survival Goal in China Trial #AntibodyDrugConjugate #CancerTreatmentInnovation #ChinaClinicalTrial #GlobalOncologyPipeline #GSK #HansohPharmaceutical #Oncology #OverallSurvival #Phase3Trial #ProgressionFreeSurvival #RisRez #SmallCellLungCancer #TargetedTherapy

https://www.europesays.com/britain/81529/ GSK Velu to List Trivitron, Neuberg Diagnostics, Maxi Vision and Kauvery Hospitals in $1 Billion IPO Push Over Next Three Years #DiagnosticsChain #EyeCare #FortuneIndia #GenomicsDiagnostics #GSK #GSKVelu #HealthcareIPOs #HospitalNetwork #IndiaHealthcare #KauveryHospitals #MaxiVision #MedicalDevices #MedicalTechnology #NeubergDiagnostics #PrivateEquity #Trivitron

Nuvalent takeover: HSR waiting period cleared, $124 per share offer | GSK SEC Filing

This Amendment No. 3 (this “Amendment”) amends and supplements the Tender Offer Statement on Schedule TO (together with any…
#EuropeSays #Britain #Europe #EU #GSK #$124pershare #HarmonyRow #HSRclearance #LetterofTransmittal #Nuvalent #NUVL #OffertoPurchase #tenderoffer
https://www.europesays.com/britain/80738/

https://www.europesays.com/britain/80738/ Nuvalent takeover: HSR waiting period cleared, $124 per share offer | GSK SEC Filing #$124PerShare #GSK #HarmonyRow #HSRClearance #LetterOfTransmittal #Nuvalent #NUVL #OfferToPurchase #TenderOffer

Alector loses GSK pact, repays $10.4M Hercules loan

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13…
#EuropeSays #Britain #Europe #EU #GSK #ALEC #Alector #biotech8-K #GSKcollaborationtermination #HerculesCapitalloanrepayment #INFRONT-3trial #materialdefinitiveagreement #PROGRESS-ADtrial
https://www.europesays.com/britain/79651/

https://www.europesays.com/britain/79651/ Alector loses GSK pact, repays $10.4M Hercules loan #ALEC #Alector #Biotech8K #GSK #GSKCollaborationTermination #HerculesCapitalLoanRepayment #INFRONT3Trial #MaterialDefinitiveAgreement #PROGRESSADTrial

AstraZeneca, GSK intensify China ties with Sino Biopharm deals

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free…
#EuropeSays #Britain #Europe #EU #GSK #AstraZeneca #China #Drugdiscovery #respiratorymedicines #Sino
https://www.europesays.com/britain/79262/

https://www.europesays.com/britain/79262/ AstraZeneca, GSK intensify China ties with Sino Biopharm deals #AstraZeneca #China #DrugDiscovery #GSK #RespiratoryMedicines #Sino

GSK offers $124 per share to acquire Nuvalent | NUVL SEC Filing

This Amendment No. 2 (this “Amendment”) amends and supplements the Tender Offer Statement on Schedule TO (together with any…
#EuropeSays #Britain #Europe #EU #GSK #$124pershare #HSRwaitingperiod #Nuvalent #NUVL #Schedule14D-9 #tenderoffer
https://www.europesays.com/britain/78877/

https://www.europesays.com/britain/78877/ GSK offers $124 per share to acquire Nuvalent | NUVL SEC Filing #$124PerShare #GSK #HSRWaitingPeriod #Nuvalent #NUVL #Schedule14D9 #TenderOffer

GSK plc (GSK) Launches Tender Offer to Acquire Nuvalent Inc. for $124 Per Share

We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. GSK plc…
#EuropeSays #Britain #Europe #EU #GSK #GSKplc #HarmonyRowAcquisitionCo. #HIVprevention #Inc. #Nuvalent #ViiVHealthcare
https://www.europesays.com/britain/73524/

https://www.europesays.com/britain/73524/ GSK plc (GSK) Launches Tender Offer to Acquire Nuvalent Inc. for $124 Per Share #GSK #GSKPlc #HarmonyRowAcquisitionCo #HIVPrevention #Inc #Nuvalent #ViiVHealthcare

GSK plc (GSK) Launches Tender Offer to Acquire Nuvalent Inc. for $124 Per Share

We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. GSK plc…
#EuropeSays #Britain #Europe #EU #GSK #GSKplc #HarmonyRowAcquisitionCo. #HIVprevention #Inc. #Nuvalent #ViiVHealthcare
https://www.europesays.com/britain/73485/

https://www.europesays.com/britain/73485/ GSK plc (GSK) Launches Tender Offer to Acquire Nuvalent Inc. for $124 Per Share #GSK #GSKPlc #HarmonyRowAcquisitionCo #HIVPrevention #Inc #Nuvalent #ViiVHealthcare

GSK launches $124-per-share Nuvalent tender offer | GSK SEC Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER…
#EuropeSays #Britain #Europe #EU #GSK #$124pershare #biopharmaM&A #cashacquisition #Form6-K #Hart-Scott-Rodino #merger #Nuvalent #Section251(h) #tenderoffer
https://www.europesays.com/britain/71723/

https://www.europesays.com/britain/71723/ GSK launches $124-per-share Nuvalent tender offer | GSK SEC Filing #$124PerShare #BiopharmaM&A #CashAcquisition #Form6K #GSK #HartScottRodino #merger #Nuvalent #Section251(h) #TenderOffer

GSK offers $124.00 cash per share for Nuvalent | NUVL SEC Filing

This Tender Offer Statement on Schedule TO (together with any amendments and supplements hereto, this “Schedule TO”) is…
#EuropeSays #Britain #Europe #EU #GSK #$124pershare #FacilityAgreement #MergerAgreement #Nuvalent #tenderoffer
https://www.europesays.com/britain/69901/